- Home » News and EventsPage 7
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Biologics’ Executive to Discuss Manufacturing Scale-up During a Pandemic
Jul 22, 2020
Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in Limoges, France
Jul 22, 2020
Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab
Jul 16, 2020
Catalent and Humanigen today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab.
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Jun 25, 2020
Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Catalent to Discuss Data-Driven Approaches for Small Molecule Drug Development at the Controlled Release Society Annual Meeting
Jun 24, 2020
Catalent today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
Jun 15, 2020
Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Catalent Partners with Spicona to Develop COVID-19 Vaccine Candidate Using GPEx® Cell Line Development Platform
Jun 10, 2020
Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.
Catalent’s Chair and CEO, John Chiminski, to Speak About R&D Leadership Through the Pandemic During BIO Digital
Jun 4, 2020
Catalent today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.
Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
May 20, 2020
Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.